EOLS· Health Care› Drug Manufacturers - Specialty & Generic

Evolus, Inc.

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Evolus is in Stage 2, the uptrend phase, now in week 18 (since Jun 18, 2026). It closed at $7.41, 20.3% below its 52-week high and above its 200-day average, which is rising.

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. More about the company

$7.41

+0.14% today

$489M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is EOLS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 19w

S3 16w

S4 35w

S4 15w

S2 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 1w → S2 7w → S3 2w → S4 6w → S1 1w → S2 19w → S3 16w → S2 13w → S3 6w → S4 7w → S1 6w → S2 1w → S1 1w → S4 35w → S1 5w → S4 15w → S1 7w → S2 18w current

Total tracked: 165 weeks across 19 stage runs.

EOLS among Drug Manufacturers - Specialty & Generic25th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…25	EOLSEvolus, Inc.	Stage 2 · wk 18	62	−7.4%

vs 52W High

-20.3%

$3.94 lo$9.30 hi

20.3% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 18

1w13w26w

Week 18, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

19.4%

200 DMA: $6.21 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.75x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.4%

+23.9%

+39.5%

YTD

+10.3%

+9.1%

Scan Membership

Breakout Watch

Latest: 2025-03-28

9 appearances in last 60 days. First seen: 2019-03-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 18 · Vol 0.75x

2026-10-21S2

Wk 18 · Vol 0.47x

2026-10-20S2

Wk 18 · Vol 0.50x

2026-10-19S2

Wk 17 · Vol 0.57x

2026-10-16S2

Wk 17 · Vol 0.80x

2026-10-15S2

Wk 17 · Vol 0.94x

2026-10-14S2

Wk 17 · Vol 1.05x

2026-10-13S2

Wk 17 · Vol 0.69x

2026-10-12S2

Wk 16 · Vol 1.06x

2026-10-09S2

Wk 16 · Vol 0.45x

2026-10-08S2

Wk 16 · Vol 1.15x

2026-10-07S2

Wk 16 · Vol 0.63x

Moving averages & range

50 DMA

$8.08

200 DMA

$6.21

52W High

$9.30

52W Low

$3.94

5D Low

$7.10

Resistance levels (recent highs)

20d High

$8.00

60d High

$9.30

120d High

$9.30

250d High

$9.30

Next resistance

+8.0%

to 20d High

Dividend Yield

0.00%

P/B -15.8

Evolus: quick answers

What stage is Evolus in?

As of Oct 22, 2026, Evolus (EOLS) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 18, 2026 and is in week 18. What the four stages mean

Is Evolus in an uptrend?

Yes. Evolus is in a Stage 2 uptrend. It trades 19.4% above its 200-day average, which is rising.

How far is Evolus from its 52-week high?

Evolus closed at $7.41 on Oct 22, 2026, 20.3% below its 52-week high of $9.30. Its 52-week low is $3.94.

How has Evolus performed over the past year?

As of Oct 22, 2026, Evolus is up 9.1% over the past year and up 10.3% so far in 2026.

Which sector and industry is Evolus in?

Evolus is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.